Valmor^TM

Indication:
Indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure and reduced ejection fraction.

Dosage & Administration:
The recommended starting dose is 49/51 mg (Sacubitril/Valsartan) twice-daily. A starting dose of 24/26 mg (Sacubitril/Valsartan) twice-daily is recommended for:
• Patients not currently taking an Angiotensin Converting Enzyme (ACE) inhibitor or an Angiotensin II Receptor Blocker (ARB) or previously taking a low dose of these agents
• Patients with severe renal impairment
• Patients with moderate hepatic impairment

Dose should be doubled after 2 to 4 weeks to the target maintenance dose of 97/103 mg (Sacubitril/Valsartan) twice-daily, as tolerated by the patient.

Preparation:
Valmor 50 Tablet: Each film coated tablet contains Sacubitril Valsartan Sodium Hemipentahydrate equivalent to Sacubitril INN 24 mg and Valsartan USP 26 mg.
Valmor 100 Tablet: Each film coated tablet contains Sacubitril Valsartan Sodium Hemipentahydrate equivalent to Sacubitril INN 49 mg and Valsartan USP 51 mg.